Clinical evidences demonstrate that anti-PD-1/anti-CTLA4 combination therapy outperforms PD-1 monotherapy, significantly improving both response rate and survival outcomes in cancer patients 42, 45. The gene discussed is CTLA4; the disease is cancer.